Long before Mylan disclosed that it paid Chairman Robert Coury $97.6 million last year, consultants advising institutional investors on how to vote at shareholder meetings had concerns about the generic drugmaker’s compensation plan.
In a 2012 nonbinding vote, shareholders rejected Mylan’s pay plan after Institutional Shareholder Services of Rockville, Md., and San Francisco-based Glass Lewis recommended no votes. Last year, Egan-Jones Proxy Services of Haverford, Pa., joined ISS and Glass Lewis in opposing Mylan’s pay policies.
The three firms have yet to issue their recommendations for Mylan’s June 22 shareholder meeting in Amsterdam, where the company reincorporated in 2015. Operations continue to be run from executive offices in Cecil.
But Mylan is warning one of the advisers that it risks making factual errors unless it allows the drugmaker to review the report before shareholders see the document.
“The facts presented in our proxy this year are complex,” four Mylan directors wrote in a letter to ISS on Tuesday. “Nobody knows the facts better than the company itself and, therefore, we believe that we can be an important resource in making sure that the report is factually accurate.”
The letter indicates the four directors met with ISS on Monday and were told that Mylan would not be afforded pre-publication review.
In an emailed statement to the Pittsburgh Post-Gazette, Mylan said its “objective is simply to ensure an accurate report.”
“Mylan has not been provided a draft of the report and understands that it will not be provided with the same opportunity to review that it has been given in the recent past,” the company wrote in the email.
ISS reaffirmed its decision Wednesday in a letter to Mylan. The letter, filed with the U.S. Securities and Exchange Commission, explained ISS’ policy of not allowing pre-publication review in the case of: special shareholder meetings; votes on a merger or acquisition proposal; when there is a fight over some other issue; or if there is an item that “ISS, in its sole discretion, considers to be of a contentious or controversial nature.” The policy protects the independence of its research and recommendations, ISS told Mylan.
The proxy adviser said Mylan can’t look at its report before it is published because four large pension funds are urging Mylan shareholders to vote against the company’s pay plan, as well as against the re-election of Mr. Coury and five other Mylan directors: Wendy Cameron, co-owner of a Washington, Pa., harness racing business; retired federal judge Robert Cindrich; retired AmerisourceBergen chief financial officer Neil Dimick; TridentUSA Health Services CEO Mark Parrish; and Randall Vanderveen, a pharmaceutical policy and economics professor at the University of Southern California.
The pension funds, which own less than 1 percent of Mylan’s shares, include retirement plans for California’s teachers, New York city and state employees, as well as PGGM, a Dutch pension plan.
“Mylan’s board reached new lows in corporate stewardship in 2016,” the pension funds wrote in a May 30 letter to shareholders, citing Mr. Coury’s “extraordinary and egregious” pay.
The funds accused Mylan of providing the equivalent of CEO pay or more to three executives — Mr. Coury, CEO Heather Bresch and president Rajiv Malik — for doing the same job. The funds said none of the executives felt the financial pain that shareholders did last year when Mylan shares tumbled 29 percent in large part because of outrage over the significant price increases for the company’s EpiPen emergency allergy shot.
In response to the funds’ letter, Mylan issued a presentation defending its pay policies and explaining that EpiPen “started a broader conversation in late summer 2016 about drug pricing that we welcome.”
According to a June 5 story in The New York Times, that conversation includes sign language.
Quoting anonymous former Mylan executives, the story indicated that Mr. Coury responded to internal concern about EpiPen price hikes by raising “both his middle fingers and explained, using colorful language, that anyone criticizing Mylan, including its employees, ought to go copulate with themselves.” He said critics in Congress, on Wall Street and at the U.S. Food and Drug Administration should do the same, the report stated.
The Times said Mylan disputed aspects of its account.
The company’s shareholders will determine in 11 days how far any discontent over the drugmaker’s pay practices extends beyond the 1 percent that the pension funds represent.
Shareholders at fewer than 1 percent of the 1,654 shareholder meetings that compensation consultant Semler Brossy has monitored this year rejected a company’s pay plan, approving the plans by an average vote of 92.4 percent in favor. Support is significantly lower when ISS recommends voting no, Semler Brossy said.
Len Boselovic: lboselovic@post-gazette.com or 412-263-1941.




Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.